JPWO2023178019A5 - - Google Patents
Info
- Publication number
- JPWO2023178019A5 JPWO2023178019A5 JP2024554636A JP2024554636A JPWO2023178019A5 JP WO2023178019 A5 JPWO2023178019 A5 JP WO2023178019A5 JP 2024554636 A JP2024554636 A JP 2024554636A JP 2024554636 A JP2024554636 A JP 2024554636A JP WO2023178019 A5 JPWO2023178019 A5 JP WO2023178019A5
- Authority
- JP
- Japan
- Prior art keywords
- fdc
- breast cancer
- dose
- trastuzumab
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269326P | 2022-03-14 | 2022-03-14 | |
| US63/269,326 | 2022-03-14 | ||
| PCT/US2023/064143 WO2023178019A1 (en) | 2022-03-14 | 2023-03-10 | Combination therapies for breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025509510A JP2025509510A (ja) | 2025-04-11 |
| JPWO2023178019A5 true JPWO2023178019A5 (https=) | 2026-03-10 |
| JP2025509510A5 JP2025509510A5 (https=) | 2026-03-10 |
Family
ID=85937455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554636A Pending JP2025509510A (ja) | 2022-03-14 | 2023-03-10 | 乳がんのための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250177364A1 (https=) |
| EP (1) | EP4493180A1 (https=) |
| JP (1) | JP2025509510A (https=) |
| KR (1) | KR20240163084A (https=) |
| CN (1) | CN118843461A (https=) |
| AU (1) | AU2023234511A1 (https=) |
| CA (1) | CA3254271A1 (https=) |
| IL (1) | IL315153A (https=) |
| MX (1) | MX2024011183A (https=) |
| TW (1) | TW202400230A (https=) |
| WO (1) | WO2023178019A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2437300A (en) | 1999-01-15 | 2000-08-01 | Infineum International Ltd | Improved fuel compositions |
| SG11201905622VA (en) | 2017-01-17 | 2019-08-27 | Genentech Inc | Subcutaneous her2 antibody formulations |
| TWI800827B (zh) * | 2020-05-12 | 2023-05-01 | 美商建南德克公司 | 使用包含gdc-9545及cdk4/6抑制劑之組合療法治療乳癌 |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
| MX2023000622A (es) | 2020-07-14 | 2023-02-22 | Genentech Inc | Ensayos para combinaciones de dosis fija. |
-
2023
- 2023-03-10 IL IL315153A patent/IL315153A/en unknown
- 2023-03-10 CN CN202380026682.0A patent/CN118843461A/zh active Pending
- 2023-03-10 MX MX2024011183A patent/MX2024011183A/es unknown
- 2023-03-10 JP JP2024554636A patent/JP2025509510A/ja active Pending
- 2023-03-10 AU AU2023234511A patent/AU2023234511A1/en active Pending
- 2023-03-10 KR KR1020247031992A patent/KR20240163084A/ko active Pending
- 2023-03-10 US US18/844,654 patent/US20250177364A1/en active Pending
- 2023-03-10 EP EP23715700.3A patent/EP4493180A1/en active Pending
- 2023-03-10 CA CA3254271A patent/CA3254271A1/en active Pending
- 2023-03-10 TW TW112109034A patent/TW202400230A/zh unknown
- 2023-03-10 WO PCT/US2023/064143 patent/WO2023178019A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tahara et al. | Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) | |
| JP2020090507A5 (https=) | ||
| IL299376A (en) | Fixed dose combination of pertuzumab plus transtuzumab | |
| JP2012522837A5 (https=) | ||
| RU2011125518A (ru) | Антиангиогенная терапия, применяемая для лечения рака молочной железы | |
| RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
| JP2020516646A5 (https=) | ||
| JPWO2020111018A5 (https=) | ||
| JP2024054117A5 (https=) | ||
| JP2024016209A5 (https=) | ||
| JPWO2023178019A5 (https=) | ||
| JP2025148449A5 (https=) | ||
| IL292332A (en) | Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab | |
| Cha et al. | A case report of a patient presented with skin ulcer after treatment of lenvatinib | |
| RU2024129464A (ru) | Комбинированная терапия рака молочной железы | |
| JPWO2020112765A5 (https=) | ||
| JPWO2021030248A5 (https=) | ||
| Zhao et al. | Efficacy of traditional Chinese medicine in the conservative management of complete small intestinal obstruction post-gastric cancer surgery: a case report | |
| CN109010495A (zh) | 一种中药组合物及其制备方法和应用 | |
| CN115243686A (zh) | 丁基苯酞及其衍生物的用途 | |
| JPWO2020159822A5 (https=) | ||
| JPWO2022221143A5 (https=) | ||
| CN113893279B (zh) | 一清颗粒与环磷酰胺联合用药在抗肿瘤治疗药物中的应用 | |
| CN104784651B (zh) | 一种制备用于治疗胃溃疡的药物制剂的方法 | |
| CN103768146B (zh) | 治疗心胃疼痛的药物组合物、药物制剂及应用和制法 |